FORTY SEVEN

forty-seven-logo

Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.

#People #Financial #Website #More

FORTY SEVEN

Social Links:

Industry:
Biotechnology Clinical Trials Health Care

Founded:
2015-01-01

Address:
Palo Alto, California, United States

Country:
United States

Website Url:
http://www.fortyseveninc.com

Total Employee:
51+

Status:
Closed

Contact:
650-352-4150

Email Addresses:
[email protected]

Total Funding:
156 M USD

Technology used in webpage:
SPF LetsEncrypt Microsoft Exchange Online Office 365 Mail IPv6 ReCAPTCHA Microsoft Azure DNS COVID-19 ReCAPTCHA V2 Pound Sterling



Current Advisors List

dennis-henner_image

Dennis Henner Board Member @ Forty Seven
Board_member
2015-01-01

ian-clark_image

Ian Clark Board Member @ Forty Seven
Board_member
2018-01-01

irving-l-weissman_image

Irving L. Weissman Board Member @ Forty Seven
Board_member
2015-01-01

Current Employees Featured

irving-l-weissman_image

Irving L. Weissman
Irving L. Weissman Founder @ Forty Seven
Founder
2014-10-14

jens-peter-volkmer_image

Jens-Peter Volkmer
Jens-Peter Volkmer Founder & VP Research & Early Development @ Forty Seven
Founder & VP Research & Early Development

mark-mccamish_image

Mark McCamish
Mark McCamish President and Chief Executive Officer @ Forty Seven
President and Chief Executive Officer
2017-05-01

norman-kruse_image

Norman Kruse
Norman Kruse Chief Patent Counsel @ Forty Seven
Chief Patent Counsel
2015-10-01

ravi-majeti_image

Ravi Majeti
Ravi Majeti Founder @ Forty Seven
Founder
2015-01-01

ann-d-rhoads_image

Ann D. Rhoads
Ann D. Rhoads Chief Financial Officer @ Forty Seven
Chief Financial Officer

Founder


irving-l-weissman_image

Irving L. Weissman

jens-peter-volkmer_image

Jens-Peter Volkmer

mark-chao_image

Mark Chao

ravi-majeti_image

Ravi Majeti

Stock Details


Company's stock symbol is NASDAQ:FTSV

Investors List

leukemia-lymphoma-society_image

Leukemia & Lymphoma Society

Leukemia & Lymphoma Society investment in Post-IPO Equity - Forty Seven

wellington-management_image

Wellington Management

Wellington Management investment in Series B - Forty Seven

sutter-hill-ventures_image

Sutter Hill Ventures

Sutter Hill Ventures investment in Series B - Forty Seven

clarus-ventures_image

Clarus Ventures

Clarus Ventures investment in Series B - Forty Seven

google-ventures_image

GV

GV investment in Series B - Forty Seven

lightspeed-venture-partners_image

Lightspeed Venture Partners

Lightspeed Venture Partners investment in Series B - Forty Seven

lightspeed-venture-partners_image

Lightspeed Venture Partners

Lightspeed Venture Partners investment in Series A - Forty Seven

sutter-hill-ventures_image

Sutter Hill Ventures

Sutter Hill Ventures investment in Series A - Forty Seven

google-ventures_image

GV

GV investment in Series A - Forty Seven

clarus-ventures_image

Clarus Ventures

Clarus Ventures investment in Series A - Forty Seven

Official Site Inspections

http://www.fortyseveninc.com

  • Host name: 40.70.27.35
  • IP address: 40.70.27.35
  • Location: Boydton United States
  • Latitude: 36.6534
  • Longitude: -78.375
  • Metro Code: 560
  • Timezone: America/New_York
  • Postal: 23917

Loading ...

More informations about "Forty Seven"

Forty Seven - Crunchbase Company Profile & Funding

Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a โ€ฆSee details»

Forty Seven Company Profile 2024: Valuation, Investors โ€ฆ

Forty Seven General Information Description. Developer of immuno-oncology therapies intended to activate macrophages intended to fight cancer. The company engages in the development of therapies based on anti-CD47 which โ€ฆSee details»

Forty Seven - Craft

Mar 3, 2020 Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights. Mar 20, 2020. Forty Seven and Rocket Pharmaceuticals โ€ฆSee details»

Forty Seven Inc. - LinkedIn

Forty Seven Inc. | 5,935 followers on LinkedIn. Helping Patients Defeat Their Cancer | With a passion for helping patients defeat their cancer, we are committed to the advancement of โ€ฆSee details»

Management | Forty Seven, Inc.

The Investor Relations website contains information about Forty Seven, Inc. 's business for stockholders, potential investors, and financial analysts.See details»

SEC Filing | Forty Seven, Inc.

Name of Issuer; Forty Seven, Inc. Street Address 1 Street Address 2; 1490 O'BRIEN DRIVE, Suite A: City State/Province/Country ZIP/PostalCode Phone Number of IssuerSee details»

Forty Seven Inc Company Profile - Forty Seven Inc Overview

Forty Seven Inc (Forty Seven), formerly CD47 Sciences Inc is a clinical-stage immuno-oncology company that focuses on the development of therapies to treat cancer. The companyโ€™s lead โ€ฆSee details»

Forty Seven Inc. Overview | SignalHire Company Profile

To connect with Forty Seven Inc. employee register on SignalHire. Organization Website: fortyseveninc.com : Social Links: Phone Number: 1-650-352-4150: Forty Seven Inc. industries โ€ฆSee details»

Company Forty Seven, Inc. - MarketScreener.com

Apr 6, 2020 Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against โ€ฆSee details»

Board of Directors - Forty Seven, Inc.

The Investor Relations website contains information about Forty Seven, Inc. 's business for stockholders, potential investors, and financial analysts.See details»

Forty Seven - Company Profile - Tracxn

Dec 9, 2024 Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business HighlightsSeeking Alpha โ€ข Mar 20, 2020 โ€ข Forty Seven WeissLaw LLP โ€ฆSee details»

Forty Seven Company Profile | Management and Employees List

Forty - Seven Inc. Primary Industries. Internet Service Providers, Website Hosting & Internet-related Services Telecommunications Hospitality Restaurants. Contact Information. โ€ฆSee details»

Forty Seven, Inc. Company Profile | Foster City, CA | Competitors ...

Find company research, competitor information, contact details & financial data for Forty Seven, Inc. of Foster City, CA. Get the latest business insights from Dun & Bradstreet.See details»

Gilead to Acquire Forty Seven for $4.9 Billion - Gilead Sciences

Mar 2, 2020 Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches โ€ฆSee details»

EIN 47-4065674 - Forty Seven, Inc., Menlo Park, California - EIN TaxId

Organization Name: Forty Seven, Inc. IRS EIN (Taxpayer Id) 47-4065674: Doing Business As: Forty Seven Inc: Type of business: Pharmaceutical Preparations: Business Address and โ€ฆSee details»

Forty Seven - Products, Competitors, Financials, Employees ...

Football club AC Romaโ€™s non-profit organization Roma Cares is similarly supported. Roma Cares was founded in 2014 with the aim of promoting education and positive values through sports. โ€ฆSee details»

FORTY SEVEN, INC. Company Profile - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for FORTY SEVEN, INC. of Palo Alto, CA. Get the latest business insights from Dun & Bradstreet.See details»

Forty Seven CEO and Key Executive Team | Craft.co

Forty Seven's President & Chief Executive Officer is Mark McCamish. Other executives include Chris H. Takimoto, Chief Medical Officer; Ann D. Rhoads, CFO and 6 others. See the full โ€ฆSee details»

Forty Seven Inc. Appoints Ian T. Clark to Board of Directors

MENLO PARK, Calif., April 30, 2018 /PRNewswire/ -- Forty Seven Inc., a clinical-stage company focused on developing checkpoint therapies to activate macrophages in the fight against โ€ฆSee details»

Fortyseven - Overview, News & Similar companies | ZoomInfo.com

Apr 10, 2020 The Hoyt Organization <25 <$5M. 2. PR Media <25 <$5M. 3. GroundFloor Media. 84. $6.5M. 4. Engage Media Communications <25 <$5M. 5. The Brack Group <25. $5.8M. 6. โ€ฆSee details»

linkstock.net © 2022. All rights reserved